IN2014DN09445A - - Google Patents
Info
- Publication number
- IN2014DN09445A IN2014DN09445A IN9445DEN2014A IN2014DN09445A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A IN 9445DEN2014 A IN9445DEN2014 A IN 9445DEN2014A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A
- Authority
- IN
- India
- Prior art keywords
- protein complexes
- viral proteins
- engineered viral
- vaccine
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644830P | 2012-05-09 | 2012-05-09 | |
| PCT/US2013/040228 WO2013169961A1 (en) | 2012-05-09 | 2013-05-09 | Conformationally specific viral immunogens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09445A true IN2014DN09445A (de) | 2015-07-17 |
Family
ID=49548782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9445DEN2014 IN2014DN09445A (de) | 2012-05-09 | 2013-05-09 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20130302366A1 (de) |
| EP (2) | EP2846828B1 (de) |
| JP (4) | JP2015518819A (de) |
| AU (5) | AU2013259548A1 (de) |
| CA (1) | CA2873048C (de) |
| IN (1) | IN2014DN09445A (de) |
| WO (1) | WO2013169961A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6685903B2 (ja) * | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質 |
| EP3027640B1 (de) | 2013-08-03 | 2018-03-07 | Avatar Medical, LLC | Influenza-hämagglutinin-proteine und verfahren zur verwendung davon |
| KR20200035115A (ko) | 2017-08-07 | 2020-04-01 | 칼더 바이오사이언시스 인코포레이티드 | 입체형태적으로 안정화된 rsv 융합전 f 단백질 |
| US11623004B2 (en) | 2018-03-16 | 2023-04-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncytial virus infection |
| MX2022014224A (es) * | 2020-05-12 | 2023-02-23 | Univ California | Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311920B1 (en) * | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| US6534064B1 (en) | 1999-10-13 | 2003-03-18 | Chiron Corporation | Stabilized protein particles for inducing cellular immune responses |
| ES2367475T3 (es) | 1999-10-15 | 2011-11-03 | Avatar Medical, L.L.C. | Proteínas estabilizadas. |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7179468B1 (en) * | 2000-06-08 | 2007-02-20 | Cornell Research Foundation, Inc. | Antigen for developing neutralizing antibodies to human immunodeficiency virus |
| EP1463521A4 (de) | 2001-12-17 | 2009-06-24 | Us Gov Health & Human Serv | Gp41-hemmer |
| WO2004069863A2 (en) | 2003-02-04 | 2004-08-19 | New York University | Constrained hiv v3 loop peptides as immunogens and receptor antagonists |
| JP5009614B2 (ja) * | 2003-07-03 | 2012-08-22 | アバター バイオテクノロジーズ，インク． | 免疫原性を低減した分子の取得方法 |
| WO2005118886A2 (en) * | 2004-06-01 | 2005-12-15 | Merck & Co., Inc. | Stable peptide mimetic of hiv gp41 fusion intermediate |
| CA2655934A1 (en) * | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| PL2338907T3 (pl) * | 2007-07-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Nowe immunogenne epitopy do immunoterapii |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| US20090246191A1 (en) * | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| PL3335728T3 (pl) * | 2008-10-10 | 2020-06-29 | Children's Medical Center Corporation | Biochemicznie stabilizowana szczepionka zawierająca trimer env wirusa HIV-1 |
| WO2011066221A1 (en) | 2009-11-24 | 2011-06-03 | International Aids Vaccine Initiative | Immunogen prioritization for vaccine design |
| EP2572196A4 (de) | 2010-05-18 | 2014-04-23 | Christopher P Marshall | Assay zur identifikation von antigenen zur aktivierung von b-zellen-rezeptoren mit neutralisierenden antikörpern |
| US20130149336A1 (en) * | 2011-10-27 | 2013-06-13 | Brian L. Hjelle | Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries |
| WO2013107290A1 (en) | 2012-01-20 | 2013-07-25 | The Government of the Hong Kong Special Administrative Region of the People's Republic of China | A novel paramyxovirus and uses thereof |
-
2013
- 2013-05-08 US US13/890,226 patent/US20130302366A1/en not_active Abandoned
- 2013-05-09 AU AU2013259548A patent/AU2013259548A1/en not_active Abandoned
- 2013-05-09 WO PCT/US2013/040228 patent/WO2013169961A1/en active Application Filing
- 2013-05-09 CA CA2873048A patent/CA2873048C/en active Active
- 2013-05-09 EP EP13787969.8A patent/EP2846828B1/de active Active
- 2013-05-09 IN IN9445DEN2014 patent/IN2014DN09445A/en unknown
- 2013-05-09 JP JP2015511675A patent/JP2015518819A/ja active Pending
- 2013-05-09 EP EP18200812.8A patent/EP3483174A1/de active Pending
- 2013-05-09 US US13/890,465 patent/US20130317205A1/en not_active Abandoned
-
2017
- 2017-02-03 US US15/424,107 patent/US10155023B2/en active Active
-
2018
- 2018-01-22 AU AU2018200502A patent/AU2018200502B2/en active Active
- 2018-05-02 JP JP2018088600A patent/JP6692853B2/ja active Active
- 2018-12-08 US US16/214,074 patent/US20190105368A1/en not_active Abandoned
-
2019
- 2019-08-16 AU AU2019216695A patent/AU2019216695A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020073065A patent/JP2020125323A/ja active Pending
- 2020-11-30 US US17/107,067 patent/US11752191B2/en active Active
-
2021
- 2021-06-21 AU AU2021204169A patent/AU2021204169B2/en active Active
-
2022
- 2022-08-12 JP JP2022128985A patent/JP7472209B2/ja active Active
-
2023
- 2023-08-25 US US18/455,787 patent/US20240238369A1/en active Pending
-
2024
- 2024-02-22 AU AU2024201200A patent/AU2024201200A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210322512A1 (en) | 2021-10-21 |
| US20180117116A1 (en) | 2018-05-03 |
| CA2873048C (en) | 2020-10-27 |
| EP2846828B1 (de) | 2018-11-21 |
| US20240238369A1 (en) | 2024-07-18 |
| JP7472209B2 (ja) | 2024-04-22 |
| JP2022163180A (ja) | 2022-10-25 |
| AU2013259548A1 (en) | 2014-11-27 |
| CA2873048A1 (en) | 2013-11-14 |
| US20130317205A1 (en) | 2013-11-28 |
| JP2015518819A (ja) | 2015-07-06 |
| JP2020125323A (ja) | 2020-08-20 |
| US11752191B2 (en) | 2023-09-12 |
| EP2846828A1 (de) | 2015-03-18 |
| AU2018200502B2 (en) | 2019-10-03 |
| EP2846828A4 (de) | 2015-07-01 |
| AU2021204169A1 (en) | 2021-07-15 |
| JP2018150330A (ja) | 2018-09-27 |
| AU2024201200A1 (en) | 2024-03-14 |
| AU2018200502A1 (en) | 2018-02-15 |
| AU2019216695A1 (en) | 2019-09-05 |
| US20190105368A1 (en) | 2019-04-11 |
| WO2013169961A1 (en) | 2013-11-14 |
| JP6692853B2 (ja) | 2020-05-13 |
| US20130302366A1 (en) | 2013-11-14 |
| EP3483174A1 (de) | 2019-05-15 |
| US10155023B2 (en) | 2018-12-18 |
| AU2021204169B2 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
| MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| MX2018009990A (es) | Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r. | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| WO2016019134A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| MX364689B (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| EA202090699A3 (ru) | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| WO2015052543A3 (en) | Malaria vaccination | |
| ZA202204981B (en) | Synthetic chimeric poxviruses | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| IN2014DN09445A (de) | ||
| MY189495A (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| TN2018000180A1 (en) | Polypeptides inhibiting cd40l | |
| MX2017008406A (es) | Conjugados de aminoacidos y peptidos y sus usos. | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
| WO2016049522A3 (en) | Compositions comprising ch505 envelopes, and trimers | |
| WO2015086354A3 (en) | Novel promiscuous hpv16-derived t helper epitopes for immunotherapy | |
| MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. | |
| WO2012103444A3 (en) | Immunogenic compositions and reagents for preparing |